VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ...

On Friday, Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $9.26 which represents a slight increase of $1.77 or 23.63% from the prior close of $7.49. The stock opened at $7.14 ...

Vir Biotechnology (VIR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick ...

Q3 2024 Earnings Call Transcript October 31, 2024 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is ...

GET MORE AI-GENERATED SIGNALS: November 05, 2024, 01:08 am ET, BY Tyler- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short VIR slightly under 9.87, target 8.38, stop loss @ 9.9 Check ...

Vir Biotechnology Inc (VIR) reports increased R&D expenses due to the Sanofi transaction, while advancing its Hepatitis and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.22 per share a year ago. These ...

Classic and modern muscle battle at Optima’s Ultimate Street Car 2024 seventh race at historic VIR! The competition continues to see who wins a spot in Vegas!

Check the time stamp on this data. Updated AI-Generated Signals for Vir Biotechnology Inc. (VIR) available here: VIR.

Revenue missed analyst estimates by 57%. Earnings per share (EPS) also missed analyst estimates by 63%. Looking ahead, ...